Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

June 21, 2024

https://www.globenewswire.com/news-release/2024/06/21/2902256/0/en/Aprea-Therapeutics-to-Host-Virtual-KOL-Event-on-APR-1051-a-Highly-Selective-and-Potentially-Best-in-Class-Oral-WEE1-Inhibitor-on-Monday-June-24-2024.html

DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq:APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET. To register, click here.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.